Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | DDO | Q99489 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466202 | 0.82 | CDK5 (0.72) | KDRCHEK1NPC1LMNAGLA | |
| SCHEMBL12559604 | 0.82 | MAOA (0.52) | NPC1LMNAGLACASP1RAB9A | |
| SCHEMBL5469347 | 0.78 | CDK5 (0.65) | KDRCHEK1NPC1LMNAGLA | |
| SCHEMBL30048517 | 0.76 | MAPT (0.66) | KDRCHEK1NPC1LMNAGLA | |
| SCHEMBL2546875 | 0.76 | MAPT (0.66) | KDRCHEK1NPC1LMNAGLA | |
| SCHEMBL5076094 | 0.74 | KDR (1.00) | KDRCHEK1NPC1RAB9ACDK5 | |
| SCHEMBL29712353 | 0.74 | KDR (0.68) | KDRCHEK1NPC1RAB9AHSD17B10 | |
| SCHEMBL2008746 | 0.74 | KDR (0.68) | KDRCHEK1NPC1RAB9AHSD17B10 | |
| SCHEMBL29370693 | 0.74 | KDR (1.00) | KDRCHEK1NPC1RAB9ACDK5 | |
| SCHEMBL3963947 | 0.72 | CDK5 (0.68) | KDRCHEK1HSD17B10CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111910208-B | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2021-07-20 | — | — | CN | claimed |
| CN-111910208-A | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2020-11-10 | — | — | CN | claimed |
| CN-111763199-B | 2-thienyl quinolinone derivative and preparation method and application thereof | 西华大学 | 2021-08-31 | — | — | CN | disclosed |
| CN-111910208-B | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2021-07-20 | — | — | CN | disclosed |
| CN-111910208-B | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2021-07-20 | — | — | CN | disclosed |
| CN-111910208-A | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2020-11-10 | — | — | CN | disclosed |
| CN-111910208-A | Electrochemical synthesis method of 3-thiophenyl quinolinone | 怀化学院 | 2020-11-10 | — | — | CN | disclosed |
| CN-111763199-A | 2-thienyl quinolinone derivative and preparation method and application thereof | 西华大学 | 2020-10-13 | — | — | CN | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | KDR 4759/4885CHEK1 221/4885NPC1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.